BSE: 543950 | NSE: YATHARTH | Hospital & Healthcare Services | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Yatharth Hospital & Trauma Care Services Ltd is a good quality company.
The key valuation ratios of Yatharth Hospital & Trauma Care Services Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Yatharth Hospital & Trauma Care Services Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 7.1% | 9.7% | 17.9% | 37.2% | 37.3% | 21.1% | - |
| Value Creation Index ⓘ | -0.5 | -0.3 | 0.3 | 1.8 | 1.7 | 0.5 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||
| Sales ⓘ | 102 | 133 | 165 | 299 | 372 | 420 | 439 |
| Sales YoY Gr. | - | 30.3% | 24.1% | 81.3% | 24.4% | 13% | - |
| Adj EPS ⓘ | 0.4 | 0.1 | 1.9 | 6.4 | 9.8 | 9.8 | 10.6 |
| YoY Gr. | - | -72.7% | 1466.7% | 241.5% | 52.7% | -0.2% | - |
| BVPS (₹) ⓘ | 8.5 | 8.6 | 10.6 | 17.1 | 26.9 | 97.5 | 102.2 |
| Adj Net Profit ⓘ | 2.9 | 0.8 | 12.3 | 42.1 | 64.2 | 84 | 91 |
| Cash Flow from Ops. ⓘ | 19 | 23.5 | 25.8 | 26.8 | 25.6 | 16 | - |
| Debt/CF from Ops. ⓘ | 6.3 | 4.8 | 4 | 4.1 | 4.4 | 0.2 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | 32.8% | 36.6% | 13% | ||||
| Adj EPS ⓘ | NA | 85.9% | 73.3% | -0.2% | ||||
| BVPSⓘ | NA | 63% | 109.6% | 262.7% | ||||
| Share Price | - | - | - | 55% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 5.2 | 1.4 | 19.6 | 46.5 | 44.6 | 16.6 | 10.6 |
| Op. Profit Mgn % ⓘ | 19.4 | 23.7 | 27 | 28.5 | 28.6 | 28.3 | 27.4 |
| Net Profit Mgn % ⓘ | 2.9 | 0.6 | 7.5 | 14.1 | 17.3 | 20 | 20.7 |
| Debt to Equity ⓘ | 2.2 | 2 | 1.5 | 1 | 0.7 | 0 | 0 |
| Working Cap Days ⓘ | 0 | 75 | 86 | 97 | 128 | 260 | 279 |
| Cash Conv. Cycle ⓘ | 0 | 9 | 24 | 42 | 61 | 88 | 266 |
Sales growth is growing at healthy rate in last 3 years 36.59%
Net Profit is growing at healthy rate in last 3 years 73.27%
Return on Equity has declined versus last 3 years average to 10.60%
Sales growth is not so good in last 4 quarters at 8.08%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 10.6 | 15.1 |
| TTM Sales (₹ Cr.) | 439 | 774 |
| BVPS (₹.) ⓘ | 102.2 | 108.6 |
| Reserves (₹ Cr.) ⓘ | 791 | 846 |
| P/BV ⓘ | 5.95 | 5.60 |
| PE ⓘ | 57.44 | 40.41 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 360.10 / 692.85 |
| All Time Low / High (₹) | 304.00 / 692.85 |
| Market Cap (₹ Cr.) | 5,220 |
| Equity (₹ Cr.) | 85.9 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 40.3 |
| Pledged * | 0.00 | 0.00 | 0.18 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|
| Sales | 102 | 133 | 165 | 299 | 372 | 420 |
| Operating Expenses ⓘ | 82 | 101 | 120 | 214 | 265 | 301 |
| Manufacturing Costs | 48 | 50 | 50 | 90 | 123 | 148 |
| Material Costs | 9 | 13 | 18 | 28 | 29 | 37 |
| Employee Cost | 18 | 22 | 32 | 57 | 57 | 69 |
| Other Costs ⓘ | 7 | 17 | 21 | 39 | 57 | 46 |
| Operating Profit ⓘ | 20 | 31 | 45 | 85 | 106 | 119 |
| Operating Profit Margin (%) | 19.4% | 23.7% | 27.0% | 28.5% | 28.6% | 28.3% |
| Other Income ⓘ | 0 | 0 | 1 | 1 | 2 | 14 |
| Interest ⓘ | 7 | 14 | 13 | 13 | 10 | 6 |
| Depreciation ⓘ | 8 | 15 | 14 | 13 | 13 | 13 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 6 | 3 | 18 | 60 | 86 | 113 |
| Tax ⓘ | 3 | 2 | 5 | 18 | 21 | 29 |
| Profit After Tax | 3 | 1 | 12 | 42 | 64 | 84 |
| PAT Margin (%) | 2.9% | 0.6% | 7.5% | 14.1% | 17.3% | 20.0% |
| Adjusted EPS (₹) | 0.4 | 0.1 | 1.9 | 6.4 | 9.8 | 9.8 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 56 | 56 | 69 | 112 | 176 | 837 | ||||
| Share Capital ⓘ | 16 | 16 | 16 | 66 | 66 | 86 | ||||
| Reserves ⓘ | 39 | 40 | 53 | 46 | 111 | 751 | ||||
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Debt | 120 | 102 | 96 | 85 | 86 | 2 | ||||
| Long Term Debt | 120 | 102 | 92 | 70 | 76 | 2 | ||||
| Short Term Debt | 0 | 0 | 4 | 15 | 10 | 0 | ||||
| Trade Payables | 12 | 11 | 13 | 16 | 11 | 12 | ||||
| Others Liabilities ⓘ | 10 | 32 | 34 | 73 | 54 | 28 | ||||
| Total Liabilities ⓘ | 197 | 202 | 211 | 286 | 326 | 878 | ||||
Fixed Assets | ||||||||||
| Gross Block | 191 | 194 | 204 | 212 | 223 | 248 | ||||
| Accumulated Depreciation | 44 | 59 | 72 | 90 | 102 | 116 | ||||
| Net Fixed Assetsⓘ | 146 | 134 | 132 | 122 | 121 | 133 | ||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | ||||
| Investmentsⓘ | 28 | 33 | 34 | 47 | 47 | 67 | ||||
| Inventories | 2 | 3 | 3 | 2 | 3 | 4 | ||||
| Trade Receivables | 13 | 18 | 32 | 76 | 86 | 143 | ||||
| Cash Equivalents | 0 | 1 | 1 | 2 | 13 | 227 | ||||
| Others Assetsⓘ | 7 | 12 | 10 | 36 | 57 | 304 | ||||
| Total Assets ⓘ | 197 | 202 | 211 | 286 | 326 | 878 | ||||
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 19 | 24 | 26 | 27 | 26 | 16 |
| PBT ⓘ | 8 | 3 | 18 | 60 | 86 | 113 |
| Adjustment ⓘ | 11 | 28 | 27 | 25 | 21 | 6 |
| Changes in Working Capital ⓘ | 2 | -5 | -18 | -49 | -49 | -67 |
| Tax Paid ⓘ | -2 | -2 | 0 | -9 | -32 | -36 |
| Cash Flow From Investing Activity ⓘ | -39 | -8 | -4 | -18 | -9 | -167 |
| Capex | -1 | -3 | -3 | -6 | -8 | -34 |
| Net Investments | -12 | -5 | 0 | -13 | 0 | -125 |
| Others ⓘ | -26 | 0 | -1 | 0 | 0 | -8 |
| Cash Flow From Financing Activityⓘ | 21 | -20 | -23 | -7 | -6 | 241 |
| Net Proceeds from Shares ⓘ | 4 | 0 | 0 | 0 | 0 | 577 |
| Net Proceeds from Borrowing ⓘ | 0 | -6 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | -5 | -13 | -12 | -12 | -9 | -4 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 22 | 0 | -11 | 4 | 2 | -332 |
| Net Cash Flow ⓘ | 2 | -4 | -1 | 1 | 11 | 89 |
| PARTICULARS | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 5.23 | 1.42 | 19.63 | 46.49 | 44.59 | 16.58 | ||||
| ROCE (%) | 7.08 | 9.73 | 17.91 | 37.19 | 37.32 | 21.06 | ||||
| Asset Turnover Ratio | 0.52 | 0.67 | 0.8 | 1.2 | 1.21 | 0.7 | ||||
| PAT to CFO Conversion(x) | 6.33 | 24 | 2.17 | 0.64 | 0.41 | 0.19 | Working Capital Days | |||
| Receivable Days | 46 | 43 | 55 | 66 | 80 | 100 | ||||
| Inventory Days | 8 | 7 | 6 | 3 | 3 | 3 | ||||
| Payable Days | 451 | 320 | 250 | 190 | 171 | 110 | ||||
The company was incorporated as ‘Yatharth Hospital & Trauma Care Services Private Limited’ in Delhi as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated February 28, 2008, issued by the RoC. Pursuant to a special resolution passed by its Shareholders on November 3, 2021, the company was converted into a public limited company and consequently, the name of the company was changed to ‘Yatharth Hospital & Trauma Care Services Limited’ and a fresh certificate of incorporation dated November 18, 2021 was issued by the RoC.
The company’s hospitals (i.e., Noida Extension Hospital and Greater Noida) are the largest private hospital in the National Capital Region of Delhi (Delhi NCR), respectively, in terms of number of beds in Fiscal 2023. The company operates three super specialty hospitals located in Delhi NCR, i.e., at Noida, Greater Noida and Noida Extension, Uttar Pradesh. Further, it acquired a 305-bedded multi-speciality hospital in Orchha, Madhya Pradesh near Jhansi, Uttar Pradesh (Jhansi-Orchha) which commenced commercial operations in from April 10, 2022, and is one of the largest hospital in Jhansi-Orchha-Gwalior region in terms of number of beds. For better and more focussed patient care, the company has carved out the super specialty as Centres of Excellence (COE) namely Centre of Medicine, Centre of General Surgery, Centre of Cardiology, Centre of Neurosciences, Centre of Nephrology & Urology, Centre of Paediatrics, Centre of Pulmonology, Centre of Gynaecology, and Centre of Orthopaedics & Spine & Rheumatology. Establishing COEs involves equipping these specialties with (i) advanced medical infrastructure; (ii) trained and experienced doctors, nursing, paramedical and other staff; and (iii) resources to provide a better healthcare experience to the patient and attendants. The company’s COEs represent its top 10 revenue-generating specialties. Its COEs are led by a team of respective domain expert doctors who are ably assisted by other doctors in its pursuit of providing better healthcare services to its patients. Further, while it has have started bone marrow and kidney transplant operations at its hospitals located in Noida Extension and Greater Noida, it also intends to introduce new specialties such as radiation therapy to its oncology department at its hospitals located in Noida Extension and Jhansi-Orchha.
The company’s hospitals have been designed to comply with international quality standards. All its hospitals are accredited by the NABH while its hospitals located at Greater Noida and Noida Extension are also accredited by NABL. All of its hospitals offer spacious suites along with modern deluxe and super deluxe rooms, and comfortable patient waiting areas. Its diagnostic areas are designed with the goals of providing patient-friendly, spacious and relaxing environments. It has advanced medical equipment such as Azurion catheterization laboratory, 1.5 Tesla wholebody MRI with optical digital broadband and embedded express coil technology for minimal patient repositioning and advanced non-contrast MR Angiography, 128 slice CT scan, endo bronchial ultrasound, nerve conduction velocity (NCV), advanced surgical equipment including Thulium Uro laser, flexible scope, advance laparoscope, advance microscopes, Cusa set. The advanced equipments provide for better and more accurate diagnosis, as well as insight into the surgical procedure, which increases surgical success rate. Some of its modular operation theatres are equipped with high efficiency particulate air (HEPA) filters and laminar flow, operating microscopes with image intensifiers. Its in-house diagnostic radiology setup and diagnostic labs are well equipped centres with comprehensive diagnostic capabilities including, haematology, biochemistry, microbiology, molecular biology and histopathology along with 24x7 in-house pharmacy shops.
Business area of the company
The company offers healthcare services across several specialties and super specialties.
Awards, accreditations & recognition
Accreditations
Awards
History and milestone
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
